Trial reportJournal of internal medicine2012
Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1).
Trial report in Journal of internal medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.The Journal of urology · 2023Guideline
- First-degree family history of breast cancer is associated with prostate cancer risk: a systematic review and meta-analysis.BMC cancer · 2019Pooled it
- Trial
- Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study.Prostate cancer and prostatic diseases · 2013Trial
- Article
- Family History of Prostate and Breast Cancer Integrated with a Polygenic Risk Score Identifies Men at Highest Risk of Dying from Prostate Cancer before Age 75 Years.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Role of single nucleotide polymorphisms of the HSD3B1 gene (rs6203 and rs33937873) in the prediction of prostate cancer risk.Molecular medicine reports · 2022Article
- Defining the Impact of Family History on Detection of High-grade Prostate Cancer in a Large Multi-institutional Cohort.European urology · 2022Article
- Family history of prostate cancer and prostate tumor aggressiveness in black and non-black men;results from an equal access biopsy study.Cancer causes & control : CCC · 2021Article
- Assessing the clinical utility of genetic risk scores for targeted cancer screening.Journal of translational medicine · 2021Article
- Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort.PloS one · 2020Article
- Family History of Breast or Prostate Cancer and Prostate Cancer Risk.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- Family history of breast cancer increases the risk of prostate cancer: results from the EPICAP study.Oncotarget · 2018Article
- Prostate cancer in men aged less than 50 years at diagnosis.World journal of urology · 2016Article
- Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.The Prostate · 2016Article
- Article
- A tale of two trials: The impact of 5α-reductase inhibition on prostate cancer (Review).Oncology letters · 2014Article
- Clinical presentation of prostate cancer in black South Africans.The Prostate · 2014Article
- Prostate cancer risk-associated genetic markers and their potential clinical utility.Asian journal of andrology · 2013Article
- A comparison of genetic risk score with family history for estimating prostate cancer risk.Asian journal of andrologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 1 country.
Funding
Abstract
backgroundTo what degree the associations between PCa risk and family history of prostate cancer (PCa) and/or breast cancer (BCa) are attributable to screening biases is unclear. We examined these questions within the REDUCE study, where biopsies were largely independent of prostate specific antigen (PSA) minimizing screening biases.
methodsData were from REDUCE, which tested dutasteride 0.5 mg daily for PCa risk reduction in men with PSA 2.5-10.0 ng mL(-1) and a negative prestudy biopsy. Among men undergoing at least one on-study biopsy with complete data (n = 6415; 78.1%), the association between family history and PCa risk was tested using multivariate logistic regression adjusting for clinicodemographic characteristics.
resultsA family history of PCa alone was associated with increased PCa diagnosis (OR: 1.47, 95%CI: 1.22-1.77). In North America, PCa family history was not related to PCa diagnosis (OR: 1.02, 95%CI: 0.73-1.44), whereas outside North America, PCa family history was significantly related to diagnosis (OR: 1.72, 95%CI: 1.38-2.15) (P-interaction = 0.01). A family history of both PCa and BCa (OR: 2.54, 95%CI: 1.72-3.75) but not BCa alone (OR: 1.04, 95%CI: 0.84-1.29) was associated with increased PCa risk versus no family history and irrespective of geographical region.
conclusionsIn REDUCE, PCa family history was significantly related to PCa diagnosis, although only for men outside North America. The presence of both PCa and BCa family history significantly increased risk versus PCa family history alone, irrespective of geographical region. Ultimately, our observations may support the need for changes in how we address family history in terms of both risk of PCa diagnosis and general risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.